693 related articles for article (PubMed ID: 34309862)
1. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
2. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
Barbanti P; Aurilia C; Egeo G; Fofi L; Cevoli S; Colombo B; Filippi M; Frediani F; Bono F; Grazzi L; Salerno A; Mercuri B; Carnevale A; Altamura C; Vernieri F
Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
[TBL] [Abstract][Full Text] [Related]
3. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
Barbanti P; Egeo G; Aurilia C; Torelli P; Finocchi C; d'Onofrio F; d'Onofrio L; Rao R; Messina S; Di Clemente L; Ranieri A; Autunno M; Sette G; Colombo B; Carnevale A; Aguggia M; Tasillo M; Zoroddu F; Frediani F; Filippi M; Tomino C; Proietti S; Bonassi S;
J Headache Pain; 2023 Mar; 24(1):30. PubMed ID: 36949388
[TBL] [Abstract][Full Text] [Related]
4. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
Barbanti P; Egeo G; Proietti S; d'Onofrio F; Aurilia C; Finocchi C; Di Clemente L; Zucco M; Doretti A; Messina S; Autunno M; Ranieri A; Carnevale A; Colombo B; Filippi M; Tasillo M; Rinalduzzi S; Querzani P; Sette G; Forino L; Zoroddu F; Robotti M; Valenza A; Camarda C; Borrello L; Aguggia M; Viticchi G; Tomino C; Fiorentini G; Orlando B; Bonassi S; Torelli P;
Neurol Ther; 2024 Jun; 13(3):611-624. PubMed ID: 38451463
[TBL] [Abstract][Full Text] [Related]
6. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
Barbanti P; Egeo G; Aurilia C; d'Onofrio F; Albanese M; Cetta I; Di Fiore P; Zucco M; Filippi M; Bono F; Altamura C; Proietti S; Bonassi S; Vernieri F;
J Headache Pain; 2022 Apr; 23(1):46. PubMed ID: 35397503
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
9. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
10. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
Ornello R; Casalena A; Frattale I; Gabriele A; Affaitati G; Giamberardino MA; Assetta M; Maddestra M; Marzoli F; Viola S; Cerone D; Marini C; Pistoia F; Sacco S
J Headache Pain; 2020 Apr; 21(1):32. PubMed ID: 32264820
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
[TBL] [Abstract][Full Text] [Related]
13. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA
Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404
[TBL] [Abstract][Full Text] [Related]
14. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
16. [The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].
Dobrynina LA; Gubanova MV; Belopasova AV; Baydina EV; Afanasev MA
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(2):74-80. PubMed ID: 35271240
[TBL] [Abstract][Full Text] [Related]
17. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
19. Timing and durability of response to erenumab in patients with chronic migraine.
Tepper SJ; Lucas S; Ashina M; Schwedt TJ; Ailani J; Scanlon J; Klatt J; Chou DE; Wang A; Paiva da Silva Lima G
Headache; 2021 Sep; 61(8):1255-1263. PubMed ID: 34363708
[TBL] [Abstract][Full Text] [Related]
20. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical Trial.
Pozo-Rosich P; Dolezil D; Paemeleire K; Stepien A; Stude P; Snellman J; Arkuszewski M; Stites T; Ritter S; Lopez Lopez C; Maca J; Ferraris M; Gil-Gouveia R
JAMA Neurol; 2024 May; 81(5):461-470. PubMed ID: 38526461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
